Endocrine Abstracts

Background: Liraglutide is a glucagon-like peptide analogue recently approved for use in children and young people for treating obesity. It is recommended for use within multidisciplinary weight management services, alongside dietetic and lifestyle interventions, in children over 12 years with severe obesity.Aim: To describe our experiences of using liraglutide in a tier 3 paediatric obesity service in a patient cohort who had previously failed to succes...

Introduction: A proportion of severe obesity is due to monogenic inheritance, however access to genetic testing is often limited which may underestimate prevalence. We report our data obtained via the Rare Obesity Advanced Diagnosis™ genetic testing program established to diagnose rare genetic causes of obesity.Methods: 49 patients (22 male) under the care of a tier 3 paediatric weight management service with early-...

Background: Children and young people living with severe obesity experience wide ranging complications of excess weight (CEW), however their prevalence is not well defined. We have evaluated baseline clinical characteristics and complications in two multi-disciplinary tier-3 paediatric weight management services in different regions of the UK.Methods: All new patients (n=185) aged 2–17 years seen in a 12-mo...

Introduction: NCMP (National Childhood Measurement Programme) data has highlighted a higher prevalence of childhood obesity in highly deprived areas, however the prevalence of complications from excess weight (CEW) in relation to social deprivation has not been previously reported. The aim of this study is to compare the demographic data along with CEW in children and young people (CYP) with obesity being managed at two different centres in the UK, with a very...